A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Trial Profile

A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Saxagliptin (Primary) ; Sitagliptin (Primary)
  • Indications Diabetes mellitus; Heart failure
  • Focus Pharmacodynamics
  • Acronyms MEASURE-HF
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Nov 2017 Planned End Date changed from 7 Mar 2019 to 8 Jul 2019.
    • 27 Nov 2017 Planned primary completion date changed from 7 Mar 2019 to 8 Jul 2019.
    • 17 Aug 2017 Planned End Date changed from 14 Sep 2018 to 7 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top